JANX
NASDAQ · Biotechnology
Janux Therapeutics Inc
$14.18
-0.37 (-2.51%)
Financial Highlights (FY 2026)
Revenue
9.98M
Net Income
-113,412,942
Gross Margin
—
Profit Margin
-1,136.3%
Rev Growth
+5.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 32.2% | 32.2% |
| Operating Margin | -1,576.7% | -1,419.0% | 12.6% | 12.7% |
| Profit Margin | -1,136.3% | -1,079.4% | 10.8% | 12.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 9.98M | 9.50M | 135.69M | 126.98M |
| Gross Profit | — | — | 43.74M | 40.93M |
| Operating Income | -157,399,123 | -134,759,523 | 17.15M | 16.11M |
| Net Income | -113,412,942 | -97,100,121 | 14.63M | 16.31M |
| Gross Margin | — | — | 32.2% | 32.2% |
| Operating Margin | -1,576.7% | -1,419.0% | 12.6% | 12.7% |
| Profit Margin | -1,136.3% | -1,079.4% | 10.8% | 12.8% |
| Rev Growth | +5.1% | +5.1% | +1.9% | +5.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 248.01M | 256.79M |
| Total Equity | — | — | 596.16M | 658.27M |
| D/E Ratio | — | — | 0.42 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -155,349,011 | -140,393,417 | 20.57M | 19.85M |
| Free Cash Flow | — | — | 20.68M | 20.15M |